Abiopharma

GlucoTrack Inc (GCTK) Announces Clinical Trial Update GlucoTrack Inc (GCTK) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: thanked, materials
• Diseases/Conditions: each account
• Collaboration: Glucotrack, Inc. Reminds Shareholders
• Updated Timeline: September 23, 2025, October 31, 2025
  • anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024